Similar User
@MaaT_Pharma
@SeventureP
@NathalieCorvaia
@HAffagard
@Katja_Stout
@djomangan
A major milestone for the global #microbiome industry was reached today as the #FDA approved the 1st fecal microbiome product in C.diff infections. After decades of research & clinical development, this is an enormous step forward for patients.Congratulations to@ferring @Rebiotix
Today marks a major milestone in the global #microbiome industry as we see the first FDA-approved microbiome product! Congratulations to @ferring & @Rebiotix With this significant regulatory milestone for microbiome therapies, we expect a significant acceleration of the field.
Ferring today announced that the @US_FDA Advisory Committee recommends approval of RBX2660, an investigational microbiota-based live biotherapeutic, studied for its potential to reduce recurrence of C. difficile infection after antibiotic treatment. bit.ly/3xJCCxi
Look what just came out! With contributions from @hugoreasoning, @PascalBoyerUSA, @dansperber @spiantado, @andrewshtulman, Ray Jackendoff, Keith Stanovich, and many others
Merci @LaTribuneEvents d'avoir invité @MaaT_Pharma à contribuer au #ForumSanteInnovation sur le thème des nouveaux médicaments innovant du futur. #microbiote #oncologie #France2030
#ForumSanteInnovation - #France2030 : quels nouveaux biomédicaments innovants d'ici 10 ans et comment les financer ? 🔸Cédric MOREAU de @BienCommunAdv 🔸Professeur Fabrice ANDRÉ du Centre @GustaveRoussy 🔸Bruno LINA, Professeur de virologie 🔸@SavitaBernal de @MaaT_Pharma
“Modulation of microbiota is the next frontier in cancer care” @Mohty_EBMT @HTID_Paris #HTID4
📢 In one hour, join industry leaders and world-renowned specialists to discuss the potential of microbiome. Watch live: lnkd.in/eiXtkBnW
📢 Should we be paying more attention to gut microbiome in cancer treatment? @Mohty_EBMT Dr Béatrice Gaugler and @Florent_Malard published in @TheLancetHaem on how gut microbiota modulation could improve outcomes in patients w/hematological malignancies. 👉thelancet.com/journals/lanha…
📄 [Press release] – MaaT Pharma strengthens its R&D activities in immuno-oncology with the appointment of Nathalie Corvaïa as Chief Scientific Officer. 👉 lnkd.in/ghF-HAda #CSO #MICROBIOME #SCIENCE
📄 [Communiqué de Presse] – MaaT Pharma renforce ses activités R&D en immuno-oncologie avec l’arrivée de Nathalie Corvaïa au poste de Directrice Scientifique. 👉lnkd.in/gVbC-Z_F #CSO #MICROBIOTE #SCIENCE
💬Today’s #MicrobiomeFact: Did you know? The gut microbiome interplays w/ the immune system. Modulating the microbiome could contribute to improve treatment outcomes in patients w/ blood cancer, esp. those receiving stem cell transplants or CAR-T cells. 👉lnkd.in/e7YgrNs6
📢 Our CEO, @HAffagard and our CFO, @SianCrouzet will attend the Investor Access Event in Paris on October,6-7 to present the Company and share our latest newsflow with investors. More info: 👉 lnkd.in/dEvN6juz #investorrelations #event #biotech
📆 [EVENEMENT VIRTUEL] J-1 : @HAffagard et @SianCrouzet participent au Séminaire Biotech de @PortzamparcBNPP où ils reviendront sur notre stratégie et notre newsflow. 💬 mardi 4 octobre 2022 - 9h à 18h. #Biotech #santé #finance #bourse #marchés #MidAndSmallCaps #CorporateAccess
Well done to the running team at @MaaT_Pharma who was running for @AssoALF to support research for patients with liquid tumors! #RunInLyon
Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice - in @TheLancetHaem @Mohty_EBMT @crsa_paris @MedecineSU @HopSaintAntoine @TheEBMT_CTIWP
Mathieu Fontaine, notre IP manager, participera à une table ronde : « Digitalisation de la R&D en #biotechnologie : challenges et enjeux » avec @SirvenCatherine et @Gencovery Inscription: lnkd.in/eDP6eUhc ⏰ 13 septembre 2022 entre 9h et 13h30 📍LifeHub Lyon
[EVEMENT] @SavitaBernal, Chief Business Officer, participera au colloque #microbiote & #santé du @Genopole Elle présentera MaaT Pharma et notre approche #clinique dans la restauration du microbiote. 👉 lnkd.in/d4axUnix #Biotech #microbiome #innovation #pharma #médicaments
@HAffagard, CEO de MaaT Pharma, et @SianCrouzet, CFO, participeront à 3 conférences investisseurs en septembre 👇 #HCWGlobalInvestment2022 par @HCWCO #LifeSciences conference par @KBCSecurities FORUM Lyon Pôle Bourse Valeurs Régionales par @lpf_officiel lnkd.in/ghUC4d9c
💬Join our CEO @HAffagard for @HTID_Paris on Oct. 13, 2022 at 5.15pm CET as he discusses the translational #microbiome #medicine to treat #cancer and infectious diseases with @IdeCremoux @Mohty_EBMT @HassaneZarour Mike Romanos Carl Bilbo 👉htfc-eu.com/htid/
📢 Today, we are proud to announce that 200 patients have been safely treated in #Europe with our #Microbiome Ecosystem Therapies, including more than 140 patients with our lead asset, #MaaT013. 👉lnkd.in/gZN6fhp #patientsafety #patientsfirst #innovation #pharma
United States Trends
- 1. Bo Nix 9.180 posts
- 2. Falcons 15,8 B posts
- 3. Ravens 82,9 B posts
- 4. Chiefs 66,9 B posts
- 5. Steelers 117 B posts
- 6. Paige 17,2 B posts
- 7. Bears 115 B posts
- 8. Packers 75,3 B posts
- 9. Broncos 23 B posts
- 10. Bills 105 B posts
- 11. WWIII 59,8 B posts
- 12. Jets 58,3 B posts
- 13. Lamar 32,8 B posts
- 14. Jennings 8.821 posts
- 15. Josh Allen 7.958 posts
- 16. Mahomes 20,3 B posts
- 17. Randle 12,2 B posts
- 18. Geno 21,9 B posts
- 19. 49ers 23,1 B posts
- 20. Worthy 48,8 B posts
Something went wrong.
Something went wrong.